Udit Verma, MD
Advertisement
Articles by Udit Verma, MD
Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Udit Verma on Regorafenib in Patients With mCRCApril 13th 2016
Advertisement
Advertisement
Trending on OncLive
1
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
2
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
3
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
4
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
5